HAS-BLED Bleeding Risk Calculator
The HAS-BLED score estimates the 1-year risk of major bleeding in patients with atrial fibrillation who are taking or being considered for anticoagulants. Select the criteria that apply to your patient and the score updates instantly, showing the risk category, estimated annual bleeding rate, and which factors are modifiable so you can act on them.
Formula
Worked example
A 72-year-old patient on warfarin with uncontrolled hypertension, a prior stroke, and concomitant aspirin use: H=1 (BP>160), S=1 (stroke), E=1 (age>65), D=1 (aspirin) = score 4. Estimated annual bleeding risk approximately 8.9%. Modifiable factors: control blood pressure and consider stopping aspirin.
What is the HAS-BLED score?
HAS-BLED is a clinical risk-scoring tool that estimates the 1-year probability of a major bleeding event in a patient with atrial fibrillation (AF) who is on or being considered for anticoagulation therapy. The score was derived and validated in 2010 by Pisters and colleagues using data from 3,978 patients enrolled in the Euro Heart Survey on AF. Each letter in the mnemonic represents one or two risk factors: Hypertension, Abnormal renal function, Abnormal liver function, Stroke history, Bleeding history or predisposition, Labile INR (for warfarin patients), Elderly (age over 65), and Drugs or alcohol use. The total score ranges from 0 to 9. A score of 3 or more is defined as high bleeding risk. The 2020 European Society of Cardiology guidelines for AF management recommend the HAS-BLED score as the preferred bleeding risk assessment tool, noting that it outperforms both the HEMORR2HAGES and ATRIA scoring systems.
How to use this calculator
Toggle each criterion on or off for the patient being assessed. Each criterion worth a point is described with the clinical definition that qualifies it. The calculator sums the active criteria and displays the total score, the approximate annual bleeding rate from the original derivation study, and the number of modifiable risk factors present. Modifiable factors are: uncontrolled hypertension (treat the blood pressure), labile INR (optimise warfarin dosing or switch to a DOAC), concomitant antiplatelet or NSAID use (review necessity), and harmful alcohol use (address drinking). Non-modifiable factors such as stroke history, age over 65, prior bleeding history, and renal or hepatic impairment cannot be reversed but should guide monitoring intensity. The labile INR criterion applies only to warfarin-treated patients; patients on DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) should leave that box unchecked.
Interpreting the score in clinical practice
A high HAS-BLED score does not automatically mean anticoagulation should be withheld. For most AF patients, the stroke risk quantified by the CHA2DS2-VASc score outweighs the bleeding risk at scores of 2 or above for men and 3 or above for women. The purpose of HAS-BLED is to identify which bleeding risk factors can be modified and to guide how closely the patient is monitored after starting anticoagulation. Patients with a score of 3 or more should have clinical reassessment every 3 to 6 months, prompt correction of any modifiable factors, and a clear plan for what would trigger a change in anticoagulation strategy. For patients on warfarin with labile INR, switching to a DOAC can remove that point from the score and meaningfully reduce bleeding risk without reducing stroke protection.
Definitions for each criterion
Hypertension: systolic blood pressure persistently above 160 mmHg and either untreated or inadequately controlled. Abnormal renal function: chronic dialysis, renal transplant, or serum creatinine above 2.26 mg/dL (200 micromol/L). Abnormal liver function: chronic hepatic disease such as cirrhosis, or biochemical evidence of significant hepatic derangement (bilirubin more than twice the upper limit of normal with AST, ALT, or alkaline phosphatase more than three times the upper limit of normal). Stroke: documented prior stroke of any type. Bleeding: prior major bleeding episode or a condition that predisposes to bleeding, including anaemia, bleeding diathesis, or thrombocytopenia. Labile INR: time in therapeutic range (TTR) below 60% for a patient treated with warfarin. Elderly: age above 65 years at the time of assessment. Drugs: regular use of antiplatelet agents (aspirin, clopidogrel, ticagrelor, prasugrel) or non-steroidal anti-inflammatory drugs. Alcohol: harmful use defined as 8 or more standard drinks per week.
HAS-BLED score interpretation
| Score | Risk category | Approx. annual bleeding rate | Clinical action |
|---|---|---|---|
| 0 | Low | 1.1% | Anticoagulation acceptable; standard follow-up |
| 1 | Low | 3.4% | Anticoagulation acceptable; standard follow-up |
| 2 | Moderate | 4.1% | Anticoagulation with attention to modifiable factors |
| 3 | High | 5.8% | Correct modifiable factors; 3-6 month review |
| 4 | High | 8.9% | Aggressive correction of modifiable factors; frequent review |
| 5 | High | 9.1% | Aggressive correction of modifiable factors; frequent review |
| 6-9 | High | >9% (estimated) | Multidisciplinary review; balance stroke vs bleed risk carefully |
Annual major-bleeding rates from the original Pisters et al. (Chest 2010) derivation cohort of 3,978 patients with atrial fibrillation. For scores 6 to 9 the event numbers in the derivation study were very small; rates above 5 should be interpreted with caution.
Frequently asked questions
Does a high HAS-BLED score mean I should stop anticoagulation?
No. A high HAS-BLED score (3 or above) means that bleeding risk factors are present and should be actively managed, not that anticoagulation must be stopped. For most patients with AF, the risk of stroke without anticoagulation outweighs the risk of bleeding. The score is a tool for identifying what to correct and how often to review the patient, not a threshold for withholding therapy.
What is a major bleeding event in the context of HAS-BLED?
In the original Pisters 2010 derivation study, major bleeding was defined as intracranial haemorrhage, a bleeding event requiring hospitalisation, a haemoglobin drop of more than 2 g/dL, or the need for a blood transfusion.
Does the labile INR criterion apply to patients on DOACs?
No. The labile INR criterion was designed for patients on warfarin, where the INR fluctuates and time in therapeutic range can be measured. Patients taking direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, dabigatran, or edoxaban do not have an INR to monitor, so this criterion should be left unchecked for them.
How often should the HAS-BLED score be recalculated?
The score should be reassessed at every clinical review, and certainly whenever the clinical picture changes: new medications are started or stopped, renal or hepatic function changes, blood pressure control improves or worsens, alcohol consumption changes, or a bleeding or thrombotic event occurs. For high-risk patients (score 3 or above), a review every 3 to 6 months is recommended by ESC guidelines.
How is HAS-BLED different from other bleeding risk scores?
HAS-BLED was the first widely adopted bleeding risk score specifically validated in AF patients, and it remains the most recommended in major guidelines. It outperforms the HEMORR2HAGES score (which requires haematocrit and genetic data), the ATRIA score (validated in a different population), and the ORBIT score for predicting bleeding in contemporary AF cohorts. Its main advantage over competitors is that it explicitly flags modifiable risk factors, making it actionable rather than merely prognostic.
Sources
- Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138(5):1093-1100.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498.